{
  "meta": {
    "title": "67_Interleukins_Growth_Factors_And_Targeted_Therapies",
    "url": "https://brainandscalpel.vercel.app/67-interleukins-growth-factors-and-targeted-therapies-1ce6de10.html",
    "scrapedAt": "2025-11-30T12:34:43.940Z"
  },
  "questions": [
    {
      "text": "What is the mechanism of action of imatinib mesylate?",
      "choices": [
        {
          "id": 1,
          "text": "Increase in metabolism of P glycoprotein"
        },
        {
          "id": 2,
          "text": "Blocking the action of P glycoprotein"
        },
        {
          "id": 3,
          "text": "Blocks the action of chimeric fusion protein of BCR-ABL"
        },
        {
          "id": 4,
          "text": "Non-competitive inhibition of ATP binding site"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Imatinib</strong> mesylate <strong>blocks</strong> the action of the&nbsp;<strong>chimeric</strong> <strong>fusion protein</strong> of BCR-ABL. It targets the <strong>BCR-ABL tyrosine kinase</strong> and inhibits the activity of the fusion protein.</p>\n<p>A single molecular event, <strong>9:22 translocation</strong>, leads to the expression of the Abelson proto-oncogene kinase (ABL) fused to BCR (breakpoint cluster region) yielding a constitutively activated protein kinase in chronic myelogenous leukemia.&nbsp;Imatinib causes remission in &gt;90% of patients in the chronic phase of CML.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB2477",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following is not a BCR-ABL tyrosine kinase inhibitor?",
      "choices": [
        {
          "id": 1,
          "text": "Bosutinib"
        },
        {
          "id": 2,
          "text": "Dasatinib"
        },
        {
          "id": 3,
          "text": "Erlotinib"
        },
        {
          "id": 4,
          "text": "Nilotinib"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Erlotinib</strong> is an epidermal growth factor receptor (<strong>EGFR</strong>) <strong>inhibitor.</strong></p>\n<p>Classification of&nbsp;<strong>BCR-ABL kinase inhibitors</strong>:&nbsp;</p>\n<ul>\n<li><strong>First-generation</strong>:<strong>&nbsp;</strong>most likely to develop resistance.\n<ul>\n<li>Imatinib&nbsp;</li>\n</ul>\n</li>\n<li><strong>Second generation</strong>: active against imatinib-resistant CML cases but not against T315I mutant cases.&nbsp;\n<ul>\n<li>Nilotinib</li>\n<li>Dasatinib&nbsp;</li>\n<li>Bosutinib&nbsp;</li>\n</ul>\n</li>\n<li><strong>Third generation</strong>: active against&nbsp;T315I mutant CML cases and other known mutant cases.&nbsp;\n<ul>\n<li>Ponatinib</li>\n</ul>\n</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB2478",
      "difficulty": "medium"
    },
    {
      "text": "A patient presented with abdominal pain. Imaging revealed a mass in the small intestine and a lesion in the liver. A diagnosis of a c-KIT positive gastrointestinal stromal tumor with liver metastasis was made on further evaluation. What is the drug of choice?",
      "choices": [
        {
          "id": 1,
          "text": "Imatinib"
        },
        {
          "id": 2,
          "text": "Bevacizumab"
        },
        {
          "id": 3,
          "text": "Denosumab"
        },
        {
          "id": 4,
          "text": "Rituximab"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The drug of choice for the management of a patient with a&nbsp;<strong>metastatic gastrointestinal stromal tumor</strong> is <strong>imatinib.&nbsp;</strong></p>\n<p>It is an <strong>oral</strong> anticancer drug that acts by <strong>inhibiting tyrosine kinase</strong> activated due to BCR-ABL fusion. It also inhibits other related tyrosine kinases and hence is used in the treatment of conditions like gastrointestinal stromal tumor (driven by a<strong> c-KIT mutation).</strong></p>\n<p>Imatinib is the agent of choice for GIST patients with metastatic disease and as adjuvant therapy for c-kit positive GIST.</p><p><span data-sheets-value=\"{&quot;1&quot;:2,&quot;2&quot;:&quot;The FDA approved Ripretinib tablets, a new kinase inhibitor as a fourth-line treatment for advanced gastrointestinal stromal tumors (GISTs). It is indicated for patients previously treated with three or more other kinase inhibitor therapies, including Imatinib.&quot;}\" data-sheets-userformat=\"{&quot;2&quot;:893,&quot;3&quot;:{&quot;1&quot;:0},&quot;5&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;6&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;7&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;8&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;9&quot;:0,&quot;11&quot;:4,&quot;12&quot;:0}\">The FDA approved ripretinib tablets, a new kinase inhibitor as a fourth-line treatment for advanced gastrointestinal stromal tumors. </span></p>\n<p><span data-sheets-value=\"{&quot;1&quot;:2,&quot;2&quot;:&quot;The FDA approved Ripretinib tablets, a new kinase inhibitor as a fourth-line treatment for advanced gastrointestinal stromal tumors (GISTs). It is indicated for patients previously treated with three or more other kinase inhibitor therapies, including Imatinib.&quot;}\" data-sheets-userformat=\"{&quot;2&quot;:893,&quot;3&quot;:{&quot;1&quot;:0},&quot;5&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;6&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;7&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;8&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;9&quot;:0,&quot;11&quot;:4,&quot;12&quot;:0}\">It is indicated for patients previously treated with three or more other kinase inhibitor therapies, including imatinib.</span></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB2479",
      "difficulty": "medium"
    },
    {
      "text": "A patient with chronic myeloid leukemia was switched to nilotinib as he showed only partial response to imatinib therapy. What is the mechanism resulting in the loss of response?",
      "choices": [
        {
          "id": 1,
          "text": "Amplification of wild-type kinase gene"
        },
        {
          "id": 2,
          "text": "Increased efflux"
        },
        {
          "id": 3,
          "text": "Point mutations in kinase domain"
        },
        {
          "id": 4,
          "text": "Overexpression of MDR gene"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The given scenario is suggestive of the <strong>development</strong> of <strong>resistance</strong> to <strong>imatinib,</strong> which is a <strong>tyrosine kinase inhibitor</strong>. This condition arises due to <strong>point mutations</strong> in three separate regions of the <strong>kinase domain</strong>.</p>\n<p>The contact points between imatinib and the enzyme become sites of mutations in drug-resistant leukemic cells and hence these <strong>mutations prevent tight binding</strong> of the <strong>drug</strong> and lock the enzyme in its open configuration (the configuration in which it has access to the substrate and is enzymatically active).</p>\n<p>Mechanisms other than BCR-ABL kinase mutations play a minor role in resistance to imatinib. They include:</p>\n<ul>\n<li>Amplification of the wild-type kinase gene has been identified in some cases.</li>\n<li>Overexpression of MDR-gene leading to increased drug efflux transporter has been shown experimentally but not implicated in clinical resistance.</li>\n</ul>\n<p>Nilotinib retains inhibitory activity in the presence of most point mutations that confer resistance to imatinib.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB2480",
      "difficulty": "medium"
    },
    {
      "text": "Imatinib is indicated in which of the following patients?<div class='question-desc-html'><ol>\n<li>53-year-old with gastrointestinal stromal tumor</li>\n<li>43-year-old with pyoderma gangrenosum</li>\n<li>38-year-old with dermatofibrosarcoma protuberans</li>\n<li>60-year-old with autoimmune hepatitis</li>\n<li>35-year-old with hypereosinophilia syndrome</li>\n</ol></div>",
      "choices": [
        {
          "id": 1,
          "text": "2 and 4 only"
        },
        {
          "id": 2,
          "text": "1, 2 and 4"
        },
        {
          "id": 3,
          "text": "1 and 5 only"
        },
        {
          "id": 4,
          "text": "1, 3 and 5"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Imatinib</strong> is the agent of <strong>choice</strong> in&nbsp;patients with<strong> metastatic GIST</strong> and as <strong>adjuvant</strong> therapy for <strong>c-kit positive</strong> GIST.&nbsp;Imatinib also shows therapeutic benefits in patients with&nbsp;<strong>hypereosinophilia syndrome</strong> and<strong> dermatofibrosarcoma protuberans&nbsp;</strong>(driven by activating mutations in the PDGFR).</p>\n<p>Imatinib is an oral anticancer drug that acts by inhibiting tyrosine kinase activated due to ABL-BCR fusion.&nbsp;Imatinib also inhibits other kinases and hence is used in the above-mentioned conditions.</p>\n<p><strong class=\"ng-binding\">Indications for imatinib:</strong></p>\n<div class=\"panel-body ng-scope\">\n<ul>\n<li><strong>BCR-ABL kinase mutations:</strong>\n<ul>\n<li>Chronic myelogenous leukemia (CML)</li>\n<li>Acute lymphoblastic leukemia (ALL)</li>\n</ul>\n</li>\n</ul>\n<ul>\n<li><strong>C-KIT mutations - </strong>gastrointestinal stromal tumors (GIST)</li>\n</ul>\n<ul>\n<li><strong>PDGFR mutations:</strong>\n<ul>\n<li>Dermatofibrosarcoma protuberans</li>\n<li>Hypereosinophilia syndrome</li>\n<li>Chronic myelomonocytic leukemia (CML)</li>\n</ul>\n</li>\n</ul>\n</div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB2482",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is a third generation BCR-ABL kinase inhibitor?",
      "choices": [
        {
          "id": 1,
          "text": "Nilotinib"
        },
        {
          "id": 2,
          "text": "Bosutinib"
        },
        {
          "id": 3,
          "text": "Ponatinib"
        },
        {
          "id": 4,
          "text": "Dasatinib"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Ponatinib</strong> is a <strong>third-generation</strong> BCR-ABL kinase inhibitor.</p>\n<p>Classification of&nbsp;<strong>BCR-ABL kinase inhibitors</strong>:&nbsp;</p>\n<ul>\n<li><strong>First-generation</strong>: most likely to develop resitance.\n<ul>\n<li>Imatinib&nbsp;</li>\n</ul>\n</li>\n<li><strong>Second-generation</strong>: active against imatinib-resistant CML cases but not against T315I mutant cases.&nbsp;\n<ul>\n<li>Nilotinib</li>\n<li>Dasatinib&nbsp;</li>\n<li>Bosutinib&nbsp;</li>\n</ul>\n</li>\n<li><strong>Third-generation</strong>: active against&nbsp;T315I mutant CML cases and other known mutant cases.&nbsp;\n<ul>\n<li>Ponatinib</li>\n</ul>\n</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC4318",
      "difficulty": "medium"
    },
    {
      "text": "A patient with trastuzumab-refractory breast cancer is started on lapatinib. Which of the following statements is true regarding this drug?",
      "choices": [
        {
          "id": 1,
          "text": "Dual inhibitor of VEGFR and HER 2 tyrosine kinase"
        },
        {
          "id": 2,
          "text": "Dual inhibitor of MET and HER 2 tyrosine kinase"
        },
        {
          "id": 3,
          "text": "Dual inhibitor of VEGFR and MET tyrosine kinase"
        },
        {
          "id": 4,
          "text": "Dual inhibitor of EGFR and HER 2 tyrosine kinase"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Lapatinib&nbsp;</strong>is a <strong>dual inhibitor</strong> of epidermal growth factor (<strong>EGFR</strong>) and human epidermal growth factor 2 (<strong>HER2</strong>) <strong>tyrosine kinase</strong>.</p>\n<p>Lapatinib in combination with capecitabine is approved for the treatment of patients with metastatic HER2-positive and trastuzumab-refractory <strong>breast cancer.</strong></p><p>Trastuzumab deruxtecan is a newer drug recently approved by the FDA for the treatment of adults with unresectable or metastatic, HER2 positive breast cancer. It is a human epidermal growth factor receptor 2 (HER2)-directed antibody and topoisomerase inhibitor(toxic to cancer cells).&nbsp;&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB2484",
      "difficulty": "medium"
    },
    {
      "text": "Which among the following is an irreversible inhibitor of EGFR tyrosine kinase?",
      "choices": [
        {
          "id": 1,
          "text": "Gefitinib"
        },
        {
          "id": 2,
          "text": "Erlotinib"
        },
        {
          "id": 3,
          "text": "Trametinib"
        },
        {
          "id": 4,
          "text": "Afatinib"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Afatinib</strong> binds covalently with epidermal growth factor receptor tyrosine kinase (<strong>EGFR-TK</strong>) also known as Her-1 receptor and <strong>inhibits</strong> it <strong>irreversibly</strong>.&nbsp;It is approved for the use of <strong>metastatic non-small cell lung cancer.</strong></p>\n<p>Gefitinib and erlotinib compete with ATP binding to EGFR and results in competitive inhibition, which is reversible.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/5e5de2d60b9f4b5cb196af855a64327fx1280x1399.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB2486",
      "difficulty": "hard"
    },
    {
      "text": "A patient undergoing treatment for colon cancer develops hypertension. Which of the following drugs is most commonly implicated?",
      "choices": [
        {
          "id": 1,
          "text": "Trastuzumab"
        },
        {
          "id": 2,
          "text": "Bevacizumab"
        },
        {
          "id": 3,
          "text": "Panitumumab"
        },
        {
          "id": 4,
          "text": "Cetuximab"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Hypertension</strong> is one of the <strong>characteristic side effects</strong> of <strong>angiogenesis inhibitors</strong> like <strong>bevacizumab</strong>.&nbsp;</p>\n<p>The mechanism is not clear but may be related to<strong> decreased</strong> endothelial <strong>nitric oxide production</strong>.&nbsp;Patients receiving higher doses and prolonged treatment might require antihypertensive medications.</p>\n<p>Bevacizumab can be used in the treatment of metastatic colon cancer, in combination with FOLFOX or FOLFIRI regimen. It can also be used in the treatment of non-small cell lung cancer.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB2492",
      "difficulty": "medium"
    },
    {
      "text": "A patient with uncontrolled diabetes is diagnosed to have diabetic macular edema. Which of the following anti-VEGF therapies is effective in the treatment of this condition?",
      "choices": [
        {
          "id": 1,
          "text": "Bevacizumab"
        },
        {
          "id": 2,
          "text": "Ranibuzumab"
        },
        {
          "id": 3,
          "text": "Aflibercept"
        },
        {
          "id": 4,
          "text": "Ramucirumab"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Aflibercept</strong> is more effective in <strong>diabetic macular edema</strong> in patients with worse baseline values of visual impairment when compared to bevacizumab and ranibizumab.</p>\n<p>All of them are <strong>administered intravitreally</strong>. Clinical trials have shown the advantage of aflibercept over&nbsp;bevacizumab and ranibizumab in visual and anatomic terms at the end of one year.&nbsp;</p>\n<p>Ramucirumab which is a monoclonal antibody against VEGFR is not indicated for diabetic macular edema.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC4345",
      "difficulty": "hard"
    },
    {
      "text": "A patient is referred to your center for the management of hepatocellular carcinoma. Imaging reveals a large lesion in the liver with multiple intrahepatic metastases. The tumor is found to be unresectable. Which of the following is considered as first-line treatment for this patient?",
      "choices": [
        {
          "id": 1,
          "text": "Sunitinib"
        },
        {
          "id": 2,
          "text": "Sorafenib"
        },
        {
          "id": 3,
          "text": "Regorafenib"
        },
        {
          "id": 4,
          "text": "Thalidomide"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Sorafenib</strong>&nbsp;is indicated as a first-line treatment for <strong>unresectable hepatocellular carcinoma</strong>. It&nbsp;is an <strong>angiogenesis</strong>&nbsp;<strong>inhibitor.</strong>&nbsp;</p>\n<p><strong>Hepatocellular carcinoma management:</strong></p>\n<ul>\n<li>Resection, ablation, and other physical measures are the mainstay.</li>\n<li>Only two drugs (angiogenesis inhibitors) are approved in this condition:\n<ul>\n<li><strong>Sorafenib</strong> (first-line)</li>\n<li><strong>Regorafenib</strong> (second-line).</li>\n</ul>\n</li>\n</ul>\n<p>Sunitinib and thalidomide are not indicated in hepatocellular carcinoma.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB2494",
      "difficulty": "medium"
    },
    {
      "text": "Thalidomide should not be used in which of the following conditions?",
      "choices": [
        {
          "id": 1,
          "text": "HIV-associated peripheral neuropathy"
        },
        {
          "id": 2,
          "text": "HIV-associated aphthous ulcers"
        },
        {
          "id": 3,
          "text": "Behcet syndrome"
        },
        {
          "id": 4,
          "text": "Erythema nodosum leprosum"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Thalidomide </strong>use is associated with<strong> peripheral neuropathy</strong> and is usually avoided in HIV-associated peripheral neuropathy as it can worsen the condition.</p>\n<p>It is being investigated as an <strong>orphan drug</strong> for:</p>\n<ul>\n<li>Recurrent aphthous ulcers</li>\n<li>GVHD</li>\n<li>Behcet syndrome</li>\n<li>primary brain malignancies</li>\n<li>Kaposi's sarcoma</li>\n<li>Crohn&rsquo;s disease.</li>\n</ul>\n<p>It is approved for use in multiple myeloma and erythema nodosum leprosum.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB2495",
      "difficulty": "medium"
    },
    {
      "text": "Use of lenalidomide over thalidomide would lead to the reduction of incidence of the following side effects, except ___________.",
      "choices": [
        {
          "id": 1,
          "text": "Constipation"
        },
        {
          "id": 2,
          "text": "Sedation"
        },
        {
          "id": 3,
          "text": "Neuropathy"
        },
        {
          "id": 4,
          "text": "Bone marrow suppression"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Lenalidomide,</strong> which is a congener of thalidomide,&nbsp;<strong>suppresses bone marrow</strong> and is associated with significant leukopenia.</p>\n<p>Lenalidomide use is associated with a&nbsp;<strong>lesser</strong>&nbsp;incidence of <strong>sedation, constipation,</strong> and <strong>neuropathy</strong> when compared to thalidomide.&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB2497",
      "difficulty": "hard"
    },
    {
      "text": "Which of the following is a proteasome inhibitor?",
      "choices": [
        {
          "id": 1,
          "text": "Paclitaxel"
        },
        {
          "id": 2,
          "text": "Bortezomib"
        },
        {
          "id": 3,
          "text": "Cetuximab"
        },
        {
          "id": 4,
          "text": "Irinotecan"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Bortezomib</strong> is a proteasome inhibitor.</p>\n<p>It is a boron-containing <strong>anticancer</strong> drug that covalently binds to the proteasome and <strong>inhibits</strong> its <strong>proteolytic activity</strong>, thereby disrupting many intracellular signaling pathways<strong>.</strong> The most important of these is nuclear factor-&kappa;B (<strong>NF-&kappa;B</strong>) <strong>mediated signaling</strong>. It is indicated in the management of <strong>multiple myeloma</strong>.</p>\n<p>Option A: Paclitaxel is a taxane.</p>\n<p>Option C: Cetuximab is a monoclonal antibody against the extracellular domain of EGFR.</p>\n<p>Option D: Irinotecan is a topoisomerase I inhibitor.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB2498",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following drugs can be used for the treatment of a patient with hormone-responsive breast cancer?",
      "choices": [
        {
          "id": 1,
          "text": "Adriamycin"
        },
        {
          "id": 2,
          "text": "Clomiphene citrate"
        },
        {
          "id": 3,
          "text": "Diethylstilbestrol"
        },
        {
          "id": 4,
          "text": "Tamoxifen"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Tamoxifen</strong> is a <strong>selective estrogen receptor modulator</strong> that is indicated for <strong>hormone-responsive breast cancer.</strong>&nbsp;</p>\n<p>It is approved for endocrine treatment of women with ER+ metastatic breast cancer or following primary tumor excision as adjuvant therapy.</p><hr><h3>Related Pearl: Hormonal therapy in breast carcinoma given for ER/PR-positive cases</h3><p><strong>Role:</strong></p>\n<ul>\n<li>Reduce risk of recurrence</li>\n<li>Reduce risk of contralateral breast cancer</li>\n<li>Reduce risk of progression of in situ to invasive carcinoma</li>\n</ul><table>\n<tbody>\n<tr>\n<td>Selective estrogen- receptor modulator</td>\n<td>Aromatase inhibitors</td>\n<td>Ovarian suppression/ ablation</td>\n</tr>\n<tr>\n<td>\n<ul>\n<li>Tamoxifen</li>\n<li>Raloxifen</li>\n<li>Arzoxifen</li>\n<li>Fenoxifen</li>\n</ul>\n</td>\n<td>\n<ul>\n<li>Anastrazole</li>\n<li>Letrozole</li>\n<li>Exemestane</li>\n</ul>\n</td>\n<td>\n<ul>\n<li>Oophorectomy</li>\n<li>GnRH analogues</li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB2503",
      "difficulty": "easy"
    },
    {
      "text": "A patient undergoing adjuvant radiotherapy for an oral malignancy is prescribed a radioprotective drug. Identify this drug.",
      "choices": [
        {
          "id": 1,
          "text": "Cetuximab"
        },
        {
          "id": 2,
          "text": "Amifostine"
        },
        {
          "id": 3,
          "text": "Cisplatin"
        },
        {
          "id": 4,
          "text": "Gemcitabine"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Amifostine</strong>&nbsp;is the <strong>radioprotective</strong> drug that has been prescribed to this patient.</p>\n<p>It is an organic thiophosphate cytoprotective agent that is <strong>indicated</strong> for the following conditions:</p>\n<ul>\n<li>Reduction of <strong>nephrotoxicity</strong> associated with <strong>cisplatin.</strong></li>\n<li>Reduction of <strong>xerostomia</strong> in patients with <strong>head</strong> and <strong>neck cancer</strong> undergoing postoperative irradiation.</li>\n</ul><hr><h3>Related Pearl: Radioprotectors and Radiosensitizers</h3><p><strong>Radioprotectors</strong>:</p>\n<p>Radioprotectors are substances that protect normal tissues from the effect of radiation. These include:</p>\n<ul>\n<li>Zinc oxide</li>\n<li>Pentoxifylline</li>\n<li>Estramustine</li>\n<li>Amifostine</li>\n<li>Chlorhexidine (radiation-induced stomatitis)</li>\n<li>Potassium iodide (for thyroid against radioactive iodine)</li>\n<li>Melatonin</li>\n<li>Antioxidants</li>\n</ul>\n<p><strong>Radiosensitizers</strong>:</p>\n<p>Radiosensitizers make the tumor more susceptible to the action of radiotherapy. These include:</p>\n<ul>\n<li>Oxygen</li>\n<li>Cisplatin</li>\n<li>5 FU</li>\n<li>Gemcitabine</li>\n<li>Nitroimidazoles</li>\n</ul>\n<p><strong>Radiation potentiators</strong>:</p>\n<p>The following drugs potentiate the action of radiation when used in conjunction:&nbsp;</p>\n<ul>\n<li>Doxorubicin</li>\n<li>Dactinomycin</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB2504",
      "difficulty": "medium"
    },
    {
      "text": "Which among the following is a cyclin-dependent kinase (CDK) 4/6 inhibitor?",
      "choices": [
        {
          "id": 1,
          "text": "Ruxolitinib"
        },
        {
          "id": 2,
          "text": "Palbociclib"
        },
        {
          "id": 3,
          "text": "Cobimetinib"
        },
        {
          "id": 4,
          "text": "Trametinib"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Palbociclib</strong> is a <strong>cyclin-dependent kinase</strong> (CDK) 4/6 inhibitor.&nbsp;It is approved for use in <strong>advanced</strong> or <strong>metastatic ER-positive</strong>&nbsp;<strong>HER2-negative</strong>&nbsp;<strong>breast cancer.</strong>&nbsp;</p>\n<p>Ruxolitinib is an inhibitor of Janus associated kinases: JAK1 and JAK2.&nbsp;</p>\n<p>Tramitenib and cobimetinib are inhibitors of serine-threonine kinases.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC4323",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following inhibits  V600E mutated BRAF?",
      "choices": [
        {
          "id": 1,
          "text": "Vemurafenib"
        },
        {
          "id": 2,
          "text": "Dabrafenib"
        },
        {
          "id": 3,
          "text": "Both A and B"
        },
        {
          "id": 4,
          "text": "Ibrutinib"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Vemurafenib</strong> and <strong>dabrafenib </strong>inhibit V600E mutated <strong>BRAF</strong> present in <strong>melanoma.</strong></p>\n<p>Both are indicated in the management of melanoma.&nbsp;</p>\n<p>The name <strong>vemuraf</strong>enib is derived from the target <strong>V</strong>600<strong>E</strong> <strong>mu</strong>tated B<strong>RAF</strong>.</p>\n<p>Ibrutinib is a Bruton tyrosine kinase inhibitor.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC4324",
      "difficulty": "medium"
    },
    {
      "text": "Which among the following is a hedgehog pathway inhibitor?",
      "choices": [
        {
          "id": 1,
          "text": "Vemurafenib"
        },
        {
          "id": 2,
          "text": "Vismodegib"
        },
        {
          "id": 3,
          "text": "Olaparib"
        },
        {
          "id": 4,
          "text": "Neratinib"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Vismodegib</strong> acts as a competitive <strong>antagonist</strong> of the SMO (smoothens hedgehog) receptor in the <strong>hedgehog signaling pathway</strong>.&nbsp;</p>\n<p>Hedgehog signaling plays a key role in stem cell regulation and tissue regeneration. Basal cell carcinoma (BCC) is associated with dysregulation of this pathway. Vismodegib is indicated in patients with <strong>metastatic</strong> or<strong> relapsed BCC.&nbsp;</strong></p>\n<p>Option A:&nbsp;Vemurafenib is a BRAF kinase inhibitor.&nbsp;</p>\n<p>Option C:&nbsp;Olaparib is an inhibitor of PARP [Poly (ADP-ribose) polymerase] enzyme.&nbsp;</p>\n<p>Option D:&nbsp;Neratinib is an irreversible inhibitor of HER-2 and EGFR.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC4325",
      "difficulty": "medium"
    },
    {
      "text": "Evaluation of a patient with CLL  showed evidence of 17p deletion. Which of the following is a BCL-2 inhibitor approved for use in this condition?",
      "choices": [
        {
          "id": 1,
          "text": "Olaparib"
        },
        {
          "id": 2,
          "text": "Rucaparib"
        },
        {
          "id": 3,
          "text": "Venetoclax"
        },
        {
          "id": 4,
          "text": "Vismodegib"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Venetoclax</strong> is a small-molecule <strong>inhibitor</strong> of <strong>BCL-2</strong> that is approved for use in <strong>CLL</strong> with a 17p deletion.</p>\n<p>Overexpression of BCL-2 has been demonstrated in CLL cells where it mediates tumor cell survival.&nbsp;Venetoclax helps restore the process of apoptosis by binding directly to the BCL-2 protein, displacing proapoptotic proteins like BIM, triggering mitochondrial outer membrane permeabilization and the activation of caspases.</p>\n<p>Olaparib and rucaparib are inhibitors of PARP [Poly (ADP-ribose) polymerase] enzymes.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC4328",
      "difficulty": "hard"
    },
    {
      "text": "Sipuleucel-T is the first vaccine approved for the treatment of cancer. This vaccine induces an immune response against which of the following?",
      "choices": [
        {
          "id": 1,
          "text": "HER2 receptors"
        },
        {
          "id": 2,
          "text": "Prostatic acid phosphatase"
        },
        {
          "id": 3,
          "text": "Vascular endothelial growth factor"
        },
        {
          "id": 4,
          "text": "Vascular endothelial growth factor receptor"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Sipuleucel-T</strong> is a cell-based approach to <strong>induce</strong> an <strong>immune response</strong> against<strong> prostatic acid phosphatase</strong> (PAP) that is commonly expressed in<strong> prostatic cancer.</strong> It is approved for use in minimally symptomatic, hormone-refractory, metastatic prostate cancer.&nbsp;</p>\n<p>Sipuleucel-T preparation is done by isolating a patient's peripheral blood cells by leukapheresis and then exposing them to PAP-GM-CSF (which is a human recombinant protein). When these treated cells are infused to a patient, the APCs present in the blood produces antibodies directed against PAP.</p>\n<p>Prostate-specific membrane antigen (PSMA) is a specific prostate epithelial cell membrane antigen, showing increased expression in prostate cancers, which is also a&nbsp;potential target for monoclonal antibody therapy.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC4341",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is not a histone deacetylase inhibitor?",
      "choices": [
        {
          "id": 1,
          "text": "Vorinostat"
        },
        {
          "id": 2,
          "text": "Romidepsin"
        },
        {
          "id": 3,
          "text": "Panabinostat"
        },
        {
          "id": 4,
          "text": "Febuxostat"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Febuxostat </strong>is a uric acid synthesis inhibitor that acts by<strong> inhibiting </strong>the enzyme<strong> xanthine oxidase</strong>&nbsp;and it is indicated in gout management.</p>\n<p>Examples of <strong>histone deacetylase inhibitors</strong> are:</p>\n<ul>\n<li>Vorinostat - cutaneous T cell lymphoma</li>\n<li>Belinostat - peripheral T cell lymphoma</li>\n<li>Romidepsin - cutaneous/peripheral T cell lymphoma</li>\n<li>Panobinostat - multiple myeloma</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB1180",
      "difficulty": "medium"
    },
    {
      "text": "A 60-year-old woman was diagnosed with melanoma. Sentinel lymph node biopsy showed malignant cells. Which of the following drugs used in this condition is a MEK inhibitor?",
      "choices": [
        {
          "id": 1,
          "text": "Dabrafenib"
        },
        {
          "id": 2,
          "text": "Vemurafenib"
        },
        {
          "id": 3,
          "text": "Trametinib"
        },
        {
          "id": 4,
          "text": "Ipilimumab"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<div class=\"ng-scope\">\n<div class=\"ng-scope\">\n<p>The scenario is suggestive of <strong>metastatic melanoma</strong> and<strong> trametinib</strong> is used in this condition. It is a <strong>reversible inhibitor</strong> of the mitogen-activated extracellular signal-regulated kinase (<strong>MEK</strong>). It inhibits the serine-threonine kinase domain of BRAF V600E mutant of MEK.</p>\n<p>It can be used as a <strong>single agent</strong> but it is more effective when used with BRAF inhibitors like dabrafenib.</p>\n<p><strong>Adverse effects</strong> of this drug include:&nbsp;</p>\n<ul>\n<li>Cutaneous rash</li>\n<li>Acneiform dermatitis</li>\n<li>Diarrhea</li>\n<li>Fatigue</li>\n<li>Nausea</li>\n<li>Lymphedema.</li>\n<li>Cardiomyopathy</li>\n<li>Hypertension</li>\n<li>Hemorrhage</li>\n<li>Interstitial lung disease</li>\n<li>Ocular toxic effects.</li>\n</ul>\n<p>Options A and B: Dabrafenib and vemurafenib are BRAF inhibitors used in metastatic melanoma.</p>\n<p>Option D: Ipilimumab is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used in metastatic or unresectable melanoma.</p>\n</div>\n</div><p>The FDA has approved the combination of the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib for the treatment of patients with<em>&nbsp;</em>BRAF-mutant unresectable or metastatic melanoma.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD1296",
      "difficulty": "medium"
    },
    {
      "text": "A 4-year-old child who was being evaluated for pancytopenia is diagnosed with acute lymphoblastic leukemia. Which of the following is the first gene therapy-based treatment approved for use in this condition?",
      "choices": [
        {
          "id": 1,
          "text": "Trastuzumab"
        },
        {
          "id": 2,
          "text": "Tisagenlecleucel"
        },
        {
          "id": 3,
          "text": "Riociguat"
        },
        {
          "id": 4,
          "text": "Dinutuximab"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Tisagenlecleucel </strong>is the first <strong>gene therapy-based treatment</strong> that is approved for use in<strong> acute lymphoblastic leukemia (ALL).</strong></p>\n<p>The therapy involves reprogramming a patient&rsquo;s own T-cells with a transgene encoding a chimeric antigen receptor (CAR) to identify and eliminate <strong>CD19-</strong>expressing malignant and normal cells.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8268",
      "difficulty": "medium"
    },
    {
      "text": "A 67-year-old man presented with fatigue and weight loss. On examination, pallor and splenomegaly were noted. Peripheral blood smear examination findings are shown in the image. Which of the following BCR-ABL tyrosine kinase inhibitors is not a first-line agent for this condition?",
      "choices": [
        {
          "id": 1,
          "text": "Imatinib"
        },
        {
          "id": 2,
          "text": "Dasatinib"
        },
        {
          "id": 3,
          "text": "Nilotinib"
        },
        {
          "id": 4,
          "text": "Bosutinib"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The given scenario and the peripheral smear findings (increased WBCs with myelocytes, metamyelocytes, and band forms), is suggestive of chronic myelogenous leukemia (<strong>CML</strong>).&nbsp;<strong>Bosutinib</strong>&nbsp;is approved for use in this condition<strong>&nbsp;</strong>only for<strong> resistant and/or intolerant </strong>cases and not in newly diagnosed cases.</p>\n<p>Agents that can be used as first-line for CML are:</p>\n<ul>\n<li>Imatinib</li>\n<li>Dasatinib</li>\n<li>Nilotinib&nbsp;</li>\n</ul>\n<p>Dasatinib and nilotinib can be used in newly diagnosed cases of CML, that are found to be imatinib-resistant.</p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/7470297a361d4f2f98615f96cafa7386.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8215",
      "difficulty": "medium"
    },
    {
      "text": "A 63-year-old postmenopausal woman came to the OPD with a 12 cm adnexal mass. Her CA-125 levels were raised and her risk of malignancy index was calculated to be 250. PET scan revealed hepatic metastases. Which PARP inhibitor can you use in her treatment?",
      "choices": [
        {
          "id": 1,
          "text": "Palbociclib"
        },
        {
          "id": 2,
          "text": "Rucaparib"
        },
        {
          "id": 3,
          "text": "Vorinostat"
        },
        {
          "id": 4,
          "text": "Romidepsin"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The clinical scenario points towards a diagnosis of metastatic ovarian cancer.<strong> Rucaparib</strong> is a poly ADP-ribose polymerase/ <strong>PARP</strong> <strong>inhibitor&nbsp;</strong>approved for the&nbsp;treatment of&nbsp;<strong>advanced ovarian cancer.</strong></p>\n<p>PARP is a nuclear protein that transfers ADP-ribose from NAD<sup><span class=\"s1\">+ </span></sup>to target proteins and this plays an important&nbsp;role in the DNA damage response. Rucaparib and <strong>olaparib</strong> are PARP inhibitors.</p>\n<p>Option A: Palbociclib&nbsp;is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. It is used in the treatment of metastatic breast cancer.&nbsp;</p>\n<p>Options C &amp; D: Vorinostat and romidepsin are histone deacetylase inhibitors.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB8260",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following conditions has hydrogen peroxide been recently approved for?",
      "choices": [
        {
          "id": 1,
          "text": "Psoriasis"
        },
        {
          "id": 2,
          "text": "Rosacea"
        },
        {
          "id": 3,
          "text": "Atopic eczema"
        },
        {
          "id": 4,
          "text": "Seborrheic keratoses"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>A <strong>topical</strong> solution of<strong>&nbsp;hydrogen peroxide</strong>&nbsp;has been approved for the treatment of <strong>raised seborrheic keratoses</strong>.</p>\n<p>Hydrogen peroxide is a <strong>keratolytic agent</strong>. Its exact mechanism of action in the treatment of seborrheic keratoses<strong>&nbsp;</strong>is not fully understood. Supraphysiologic concentrations may cause oxidative damage and death to seborrheic keratosis cells.</p>\n<p>Hydrogen peroxide is commonly used as a <strong>disinfectant</strong> to <strong>clean wounds</strong>. It can also be used as a <strong>mouthwash</strong>.&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC5666",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following conditions is apalutamide approved for?",
      "choices": [
        {
          "id": 1,
          "text": "Breast cancer"
        },
        {
          "id": 2,
          "text": "Colon cancer"
        },
        {
          "id": 3,
          "text": "Prostate cancer"
        },
        {
          "id": 4,
          "text": "Gastric cancer"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Apalutamide</strong>&nbsp;is an&nbsp;<strong>androgen receptor inhibitor</strong> indicated for the treatment of patients with non-metastatic castration-resistant<strong> prostate cancer.</strong></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC2474",
      "difficulty": "medium"
    },
    {
      "text": "A 60-year-old woman was diagnosed with melanoma. Sentinel lymph node biopsy showed malignant cells.  Which among the following is a recombinant interleukin-2 preparation approved for use in this condition?",
      "choices": [
        {
          "id": 1,
          "text": "Denileukin diftitox"
        },
        {
          "id": 2,
          "text": "Aldesleukin"
        },
        {
          "id": 3,
          "text": "Imatinib"
        },
        {
          "id": 4,
          "text": "Nilotinib"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The clinical scenario is suggestive of <strong>metastatic melanoma</strong>.&nbsp;The recombinant interleukin-2 (IL-2) preparation that is approved for use in metastatic melanoma is&nbsp;<strong>aldesleukin.</strong>&nbsp;It acts as an&nbsp;<strong>IL-2 agonist</strong> and is also approved for use in metastatic renal cell cancer.</p>\n<p><strong>Denileukin diftitox</strong> is an immunotoxin made from the recombinant combination of IL-2 and the catalytically active fragment of diphtheria toxin.&nbsp;It is approved for use in <strong>cutaneous T cell lymphoma.</strong></p>\n<p>Imatinib and nilotinib are a BCR/ABL tyrosine kinase inhibitor.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB2502",
      "difficulty": "medium"
    },
    {
      "text": "Denileukin diftitox, a drug approved for the treatment of recurrent/refractory cutaneous T-cell lymphomas, is an immunotoxin made of:",
      "choices": [
        {
          "id": 1,
          "text": "Fusion protein of IL-2 and pertussis toxin"
        },
        {
          "id": 2,
          "text": "Fusion protein of IL-2 and diptheria toxin"
        },
        {
          "id": 3,
          "text": "Monoclonal antibody against CD33"
        },
        {
          "id": 4,
          "text": "Monoclonal antibody against CD30"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Denileukin diftitox</strong> is an <strong>immunotoxin</strong> made from the genetic recombination of <strong>IL-2</strong> and the catalytically active fragment of <strong>diphtheria toxin</strong>.&nbsp;</p>\n<p>It is indicated for advanced <strong>cutaneous T-cell lymphoma</strong> in patients with &gt;20% of T cells expressing the surface marker CD25.&nbsp;After binding to the IL-2 receptors, it is internalized by endocytosis.&nbsp;The active fragment of <strong>diphtheria toxin</strong> then is released into the cytosol, where it <strong>inhibits protein synthesis</strong> through ADP ribosylation, leading to <strong>cell death</strong>.</p>\n<p>Immunotoxins are proteins that contain a toxin along with an antibody that binds specifically to target cells.</p>\n<p><strong>Antibody-drug conjugates</strong> are complex molecules composed of an&nbsp;antibody&nbsp;linked to a biologically active&nbsp;cytotoxic&nbsp;(anticancer) drug. These antibody-targeted drug therapies are cell-specific to kill efficiently the target cells that bind and internalize the drug conjugate. Examples are:</p>\n<dl class=\"article-list\">\n<dt></dt>\n</dl>\n<ul>\n<li><strong>Gemtuzumab&nbsp;ozogamicin -&nbsp;</strong>Monoclonal antibody against CD33 linked to a semisynthetic derivative of calicheamicin, a potent antitumor antibiotic.&nbsp;It was approved for the treatment of acute myeloid leukemia.</li>\n<li class=\"p1\"><strong>Brentuximab vedotin -&nbsp;</strong>Anti-CD30 IgG1 monoclonal antibody linked with the microtubule-disrupting agent MMAE.&nbsp;It is used for the treatment of Hodgkin and anaplastic lymphoma.</li>\n<li class=\"p1\"><strong>Ado-trastuzumab emtansine -&nbsp;</strong>It<strong>&nbsp;</strong>combines the HER2-targeted properties of trastuzumab with the antimicrotubule agent DM1 (derived from maytansine), allowing preferential intracellular drug delivery to HER2+ cells.&nbsp;It is used in the treatment of HER+ breast cancer.</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC6499",
      "difficulty": "easy"
    }
  ]
}